✦ LIBER ✦

286 Generation of a recombinant humanized anti-insulin-like growth factor receptor type I antibody (h7C10) with an antitumor activity in a variety of human cancer xenograft models

✍ Scribed by I. Goetsch; A. Gonzalez; A. Beck; J.F. Haeuw; N. Corvaia

Book ID: 118621469
Publisher: Elsevier Science
Year: 2004
Tongue: English
Weight: 288 KB
Volume: 2
Category: Article
ISSN: 1359-6349
DOI: 10.1016/s1359-6349(04)80294-5

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A recombinant humanized anti-insulin-lik

A recombinant humanized anti-insulin-like growth factor receptor type I antibody (h7C10) enhances the antitumor activity of vinorelbine and anti-epidermal growth factor receptor therapy against human cancer xenografts

✍ Liliane Goetsch; Alexandra Gonzalez; Olivier Leger; Alain Beck; Petrus J. Pauwel 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 French ⚖ 959 KB

## Abstract Interaction of insulin‐like growth factor receptor I (IGF‐IR) with its ligands has been reported to induce cell proliferation, transformation and blockade of cell apoptotic functions. IGF‐IR is overexpressed on numerous tumor cell types and its blockade could be of importance for anti‐c

Superior Antitumor Activity of a Novel B

Superior Antitumor Activity of a Novel Bispecific Antibody Cotargeting Human Epidermal Growth Factor Receptor 2 and Type I Insulin-like Growth Factor Receptor

✍ Chen, C.; Zhang, Y.; Zhang, Y.; Li, J.; Tsao, S. W.; Zhang, M.-Y. 📂 Article 📅 2013 🏛 American Association for Cancer Research 🌐 English ⚖ 767 KB

195 POSTER In vitro and in vivo inhibiti

195 POSTER In vitro and in vivo inhibition of functional responses at insulin-like growth factor-1/insulin hybrid receptors by h7C10, a novel humanized anti-IGF-1R monoclonal antibody

✍ T. Wurch; G. Pandini; B. Akla; N. Corvaia; A. Belfiore; L. Goetsch 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 56 KB

Functional responses and in vivo anti-tu

Functional responses and in vivo anti-tumour activity of h7C10: A humanised monoclonal antibody with neutralising activity against the insulin-like growth factor-1 (IGF-1) receptor and insulin/IGF-1 hybrid receptors

✍ Giuseppe Pandini; Thierry Wurch; Barbara Akla; Nathalie Corvaia; Antonino Belfio 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 425 KB

Safety, Tolerability, Pharmacokinetics a

Safety, Tolerability, Pharmacokinetics and Antitumor Activity of Ganitumab, an Investigational Fully Human Monoclonal Antibody to Insulin-like Growth Factor Type 1 Receptor, Combined with Gemcitabine as First-line Therapy in Patients with Metastatic Pancreatic Cancer: A Phase 1b Study

✍ Okusaka, T.; Ikeda, M.; Fukutomi, A.; Kobayashi, Y.; Shibayama, K.; Takubo, T.; 📂 Article 📅 2014 🏛 Oxford University Press 🌐 English ⚖ 157 KB